Investigational drug · Phase 3
Volrustomig
Also called: MEDI5752
Not approved by FDA. In 13 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
13
13 still active
All registered trials
20
Any phase or sponsor naming "Volrustomig"
First trial start
2020
Jun 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Volrustomig", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Non-small Cell Lung Cancer
- Biliary Tract Cancer
- Locally Advanced Cervical Cancer
- Unresectable Pleural Mesothelioma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Metastatic Colorectal Cancer
- Endometrial Cancer
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Volrustomig" as an intervention, largest first.
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06129864 · 1,145 participants (planned) · Start Dec 14, 2023 · Primary completion Apr 17, 2030
Drug: volrustomig · For: Locally Advanced Head and Neck Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Prescott Valley, Arizona · 306 sites in all
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05984277 · 895 participants · Start Oct 24, 2023 · Primary completion Aug 17, 2026
Drug: Volrustomig; Pembrolizumab and 3 more · For: Metastatic Non-small Cell Lung Cancer
Sites: Hot Springs, Arkansas; Springdale, Arkansas; Long Beach, California · 231 sites in all
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06097728 · 863 participants · Start Nov 9, 2023 · Primary completion Nov 16, 2028
Drug: Volrustomig; Pemetrexed and 4 more · For: Unresectable Pleural Mesothelioma
Sites: Santa Rosa, California; Aurora, Colorado; Jacksonville, Florida · 151 sites in all
- Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06079671 · 800 participants (planned) · Start Sep 22, 2023 · Primary completion Nov 26, 2027
Drug: Volrustomig · For: Locally Advanced Cervical Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 205 sites in all
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05061550 · 630 participants (planned) · Start Apr 14, 2022 · Primary completion May 28, 2030
Drug: Durvalumab; Oleclumab and 10 more · For: Non-small Cell Lung Cancer
Sites: Little Rock, Arkansas; Los Angeles, California; Oakland, California · 97 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05489211 · 454 participants (planned) · Start Sep 6, 2022 · Primary completion Oct 1, 2027
Drug: Datopotamab deruxtecan (Dato-DXd); Capecitabine and 7 more · For: Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer and 4 more
Sites: Los Angeles, California; San Diego, California; Santa Rosa, California · 96 sites in all
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04379596 · 452 participants · Start Jun 3, 2020 · Primary completion May 4, 2027
Drug: Fluorouracil (5-FU); Capecitabine and 8 more · For: Gastric Cancer
Sites: Baltimore, Maryland; Boston, Massachusetts; New York, New York · 71 sites in all
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT04686305 · 304 participants (planned) · Start Mar 9, 2021 · Primary completion Jun 30, 2027
Drug: T-DXd; Durvalumab and 5 more · For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sites: Duarte, California; Newport Beach, California; Orange, California · 91 sites in all
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05775159 · 294 participants (planned) · Start Apr 24, 2023 · Primary completion Oct 27, 2026
Drug: Volrustomig; Bevacizumab and 4 more · For: Hepatocellular Carcinoma; Biliary Tract Cancer
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 46 sites in all
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06535607 · 257 participants (planned) · Start Aug 22, 2024 · Primary completion Nov 30, 2028
Drug: Volrustomig; Cisplatin and 3 more · For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy); Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) and 2 more
Sites: Los Angeles, California; Baltimore, Maryland; New York, New York · 98 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Retracted: Volrustomig/Rilvegostomig related "triple M"-myasthenia gravis and overlap syndrome.
Cooksley T, Keh RYS, Weaver JMJ · Postgrad Med J 2026
- Retraction of: Volrustomig/Rilvegostomig related "triple M"-myasthenia gravis and overlap syndrome.
· Postgrad Med J 2026
- Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig.
Park JC, Gainor JF · Clin Cancer Res 2026
- Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.
Tran B, Voskoboynik M, Kim SW, et al. · Clin Cancer Res 2026
- The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities.
ElBeblawy R, Jani C, Pérez-Granado J, et al. · Cancer Med 2025
- Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer.
Bose CK, Basu N · J Gynecol Oncol 2024
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.